02/08/2006,10540276.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXY1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9	MAR 22	EMBASE is now updated on a daily basis
NEWS 10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17	MAY 11	KOREAPAT updates resume
NEWS 18	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 19	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 20	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 21	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS EXPRESS		FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items
NEWS IPC8		For general information regarding STN implementation of IPC 8
NEWS X25		X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:01:19 ON 13 JUN 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:01:25 ON 13 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUN 2006 HIGHEST RN 887497-01-0
DICTIONARY FILE UPDATES: 12 JUN 2006 HIGHEST RN 887497-01-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10540276.str





chain nodes :
6 7 8 11 12
ring nodes :
1 2 3 4 5
chain bonds :
1-11 2-12 4-6 6-7 6-8
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-11 2-3 2-12 3-4 4-5 4-6 6-7 6-8

G1:C,S

G2:Hy,Cy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 11:CLASS
12:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,S

G2 Hy,Cy

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 17:01:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     3930 TO ITERATE

 50.9% PROCESSED     2000 ITERATIONS                                32 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         74841 TO    82359
PROJECTED ANSWERS:              782 TO     1732

L2            32 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 17:01:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    78731 TO ITERATE

100.0% PROCESSED   78731 ITERATIONS                            1377 ANSWERS
SEARCH TIME: 00.00.02

L3          1377 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                          SINCE FILE     TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              166.94     167.15

FILE 'HCAPLUS' ENTERED AT 17:02:17 ON 13 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 13 Jun 2006 VOL 144 ISS 25
FILE LAST UPDATED: 12 Jun 2006 (20060612/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 29 L3

=> d ed abs ibib hitstr 1-29

L4 ANSWER 1 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 19 May 2006
GI



AB Title compds. [I, II, III; wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH2, CO2, OCO, SO2, CO, CS, CONH, CSNH, etc.; with

provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca2+ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide (IV)•TFA. The latter demonstrated MCH antagonist activity with an IC50 value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data).

ACCESSION NUMBER: 2006:464826 HCAPLUS
TITLE: Preparation of quinoline, tetrahydroquinazoline, and pyrimidine derivatives as MCH antagonist for treatment of CNS disorders
INVENTOR(S): Sekiguchi, Yoshinori; Kanuma, Yukihiro; Omodera, Katsunori; Busujima, Takeshi; Tran, Thuy-Ahn; Han, Sangdong; Casper, Martin; Brian, A. Kramer; Semple, Graeme; Zou, Ning
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan; Arena Pharmaceutical Inc.
SOURCE: Jpn. Kokai Tokkyo Koho, 781 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 2006124387	A2	20060518	JP 2005-286311		20050930
PRIORITY APPLN. INFO.:			JP 2004-287659	A	20040930

IT 769183-15-5P 769184-55-6P 769185-93-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as MCH antagonist for treatment of CNS disorders)
RN 769183-15-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[cis-4-[[4-(dimethylamino)-2-quinolinyl]amino]cyclohexyl]-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 769184-55-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[cis-4-[[4-(dimethylamino)-2-pyrimidinyl]amino]cyclohexyl]-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 769185-93-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-2-quinazolinyl]amino]cyclohexyl]-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 2 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 11 Apr 2006
GI



I

AB Pyrrolecarboxamide derivs. (shown as I; other Markush structures for pyrrolecarboxamides are defined in the claims; variables defined below; e.g. 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid N-[4-(sulfamoyl)phenyl]amide (II)), compns. and methods for modulating the activity of receptors are provided. In particular compds. and compns. are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of ≥1 symptoms of disease or disorder directly or indirectly related to the activity of the receptors. Semiquant. IC50 values for antagonist activity of 23 examples of I are tabulated and compared to the activity of the Spironolactone control. For I: R1 and R2 = H, halo, cyano, or (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl, or -OR9, -SR9, -N(R9)2, -C(O)OR9 or -C(O)N(R9)2; R3 = H, halo, cyano, (un)substituted alkyl, (un)substituted alkenyl or (un)substituted alkynyl; R4 is H, -C(O)R9, -S(O)2R9, or (un)substituted alkyl, alkenyl or alkynyl, or R4 is (un)substituted cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl; R6 is H or (un)substituted alkyl; R7 is (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl; addnl. details are given in the claims. Although the methods of preparation are not claimed, prepns. and/or characterization data for many examples of I are included. For example, II was prepared in 5 steps (50, 37, 62, 64, and 66 % yields, resp.) starting with preparation of 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole from 4-fluoro-2-(trifluoromethyl)aniline and 2,5-hexanedione, followed by preparation of the following intermediates: 1-(4-fluoro-2-trifluoromethylphenyl)-2,5-dimethyl-1H-pyrrole-3-carboxaldehyde, 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid, and 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole-3-carbonyl chloride and finally amide formation with sulfanilamide.

ACCESSION NUMBER: 2006:332235 HCAPLUS
DOCUMENT NUMBER: 144:350539
TITLE: Preparation of pyrrolecarboxamide derivatives as mineralocorticoid receptor antagonists for use against cancer and other disorders
INVENTOR(S): Canne Bannen, Lynne; Chen, Jeff; Dalrymple, Lisa Esther; Flatt, Brenton T.; Forsyth, Timothy Patrick; Gu, Xiao-Hu; Mac, Morrison B.; Mann, Larry W.; Mann, Grace; Martin, Richard; Mohan, Raju; Murphy, Brett; Nyman, Michael Charles; Stevens, William C., Jr.; Wang, Tie-Lin; Wong, Yong; Wu, Jason H.
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 477 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012642	A2	20060202	WO 2005-US26916	20050730

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-592439P P 20040730
US 2004-592469P P 20040730

OTHER SOURCE(S): MARPAT 144:350539

IT 880779-30-6P, 5-(4-Fluorophenyl)-2-methyl-1-(2-trifluoromethylphenyl)-1H-pyrrole-3-carboxylic acid N-(4-methylsulfonylphenyl)amide 880779-31-7P, 1,5-Bis(4-fluorophenyl)-2-methyl-1H-pyrrole-3-carboxylic acid N-(4-methylsulfonylphenyl)amide 880779-32-8P, 5-(4-Fluorophenyl)-2-methyl-1-(2-trifluoromethylphenyl)-1H-pyrrole-3-carboxylic acid N-(3-methoxy-4-sulfamoylphenyl)amide 880779-33-9P, 5-(4-Fluorophenyl)-2-methyl-1-(2-trifluoromethylphenyl)-1H-pyrrole-3-carboxylic acid dimethylamide 880779-73-7P, 4-Methyl-N-[4-(methylsulfonyl)phenyl]-1-phenyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrrolecarboxamide derivs. as mineralocorticoid receptor antagonists for use against cancer and other disorders)

RN 880779-30-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-methyl-N-[4-(methylsulfonyl)phenyl]-1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 880779-31-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1,5-bis(4-fluorophenyl)-2-methyl-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 880779-32-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(aminosulfonyl)-3-methoxyphenyl]-5-(4-fluorophenyl)-2-methyl-1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 880779-33-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-N,N,2-trimethyl-1-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 880779-73-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-methyl-N-[4-(methylsulfonyl)phenyl]-1-phenyl-5-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 30 Dec 2005
GI



I

AB The invention provides compns. adapted to enhance reverse cholesterol transport in mammals and which are suitable for oral delivery and useful in the treatment and/or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases. Mediators of reverse cholesterol transport comprise a structure having components A, B and C, where A comprises an acidic moiety having an acidic group or a bioisostere, B comprises an aromatic or lipophilic moiety having at least a portion of HMGCoA reductase inhibitor or an analog, and C comprises a basic moiety having a basic group or bioisostere. An example describes the synthesis of lipophilic group-modified peptide sequence I.TFA based on atorvastatin.

ACCESSION NUMBER: 2005:1354478 HCAPLUS
DOCUMENT NUMBER: 144:88561
TITLE: Preparation of amino acid heterocyclic derivatives for treatment of hyperlipidemia and related diseases
INVENTOR(S): Sircar, Jagadish C.; Thomas, Richard J.; Khatuya, Haripada; Nikoulin, Igor
PATENT ASSIGNEE(S): Avanir Pharmaceuticals, USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123686	A1	20051229	WO 2005-US20660	20050609
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006009487	A1	20060112	US 2005-149067	20050609

PRIORITY APPLN. INFO.: US 2004-578227P P 20040609

IT 872406-24-1P 872406-25-2P 872406-26-3P
872406-27-4P 872406-28-5P 872406-29-6P
872406-30-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid heterocyclic derivs. for treatment of hyperlipidemia and related diseases)

RN 872406-24-1 HCAPLUS
CN Pentanoic acid, 4-[[[4-[[2-(acetylamino)-5-[(aminoiminomethyl)amino]-1-oxopentyl]amino]-2-methyl-1,5-diphenyl-1H-pyrrol-3-yl]carbonyl]amino]-5-amino-5-oxo- (9CI) (CA INDEX NAME)



RN 872406-25-2 HCAPLUS
CN Butanoic acid, 4-[[[4-[[5-[(aminoiminomethyl)amino]-1-oxopentyl]amino]-2-methyl-1,5-diphenyl-1H-pyrrol-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 872406-26-3 HCAPLUS
CN Pentanoic acid, 4-(acetylamino)-5-[[4-[[[1-(aminocarbonyl)-4-[(aminoiminomethyl)amino]butyl]amino]carbonyl]-5-methyl-1,2-diphenyl-1H-pyrrol-3-yl]amino]-5-oxo- (9CI) (CA INDEX NAME)



RN 872406-27-4 HCAPLUS
CN Pentanoic acid, 5-[[4-[[[4-[(aminoiminomethyl)amino]butyl]amino]carbonyl]-5-methyl-1,2-diphenyl-1H-pyrrol-3-yl]amino]-5-oxo- (9CI) (CA INDEX NAME)



RN 872406-28-5 HCAPLUS
CN Benzoic acid, 3-[[[4-[[2-(acetylamino)-5-[(aminoiminomethyl)amino]-1-oxopentyl]amino]-2-methyl-1,5-diphenyl-1H-pyrrol-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 872406-29-6 HCAPLUS
CN Benzoic acid, 3-[[[4-[[5-[(aminoiminomethyl)amino]-1-oxopentyl]amino]-2-methyl-1,5-diphenyl-1H-pyrrol-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 872406-30-9 HCAPLUS
CN Pentanoic acid, 5-[[4-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-5-methyl-1,2-diphenyl-1H-pyrrol-3-yl]amino]-5-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 02 Sep 2005
GI



I



II

AB The title compds. I [R1 = substituted alkoxy, sulfonyl, sulfonamide or silanyl; Ra = halo, alkyl or alkoxy; m, n = 0-3; R2 = alkyl, alkoxy, etc; R3 = H, alkyl, alkoxy, etc.; R4 = some carbonyl, etc.; R5 = H or alkyl, and pharmaceutically acceptable salts and solvates thereof], which are active in the CB1 receptor (IC50 < 1 μM) and believed to be selective CB1 antagonists or inverse agonists. were prepared As an example, condensation of Et acetoacetate with 2.2',4'-trichloroacetophenone using NaH as base (37%) followed by cyclization with 4-benzyloxyaniline hydrochloride (39%) gave pyrrole carboxylate II (R = OEt), which was hydrolyzed with NaOH and then coupled with 1-aminopiperidine to afford amide II (R = 1-piperidinylamino). Therefore, I and their pharmaceutical compns. may be used in the treatment of obesity, psychiatric disorders, neurol. disorders and so on.

ACCESSION NUMBER: 2005:962204 HCAPLUS
DOCUMENT NUMBER: 143:248281

02/08/2006,10540276.trn

TITLE: Preparation of pyrrole-3-carboxamide derivatives for the treatment of obesity and other diseases
INVENTOR(S): Bjornse, Magnus; Cheng, Leifeng; Elebring, Thomas; Boije, Anna Maria; Alstermark Lindstedt, Eva-Lotte
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080328	A1	20050901	WO 2005-GB588	20050217

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2004-3780 A 20040220
OTHER SOURCE(S): MARPAT 143:248281
IT 863332-15-4P, 1-[4-(Benzyloxy)phenyl]-5-(2,4-dichlorophenyl)-2-methyl-N-(piperidin-1-yl)-1H-pyrrole-3-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrrolecarboxamides for treatment of obesity and other diseases)
RN 863332-15-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dichlorophenyl)-2-methyl-1-[4-(phenylmethoxy)phenyl]-N-1-piperidinyl- (9CI) (CA INDEX NAME)



IT 863332-18-7P, 4-[5-(2,4-Dichlorophenyl)-2-methyl-3-[[(piperidin-1-yl)amino]carbonyl]-1H-pyrrol-1-yl]phenyl trifluoromethanesulfonate
863332-22-3P, 5-(2,4-Dichlorophenyl)-2-methyl-N-(piperidin-1-yl)-1-[4-(3,3,3-trifluoropropoxy)phenyl]-1H-pyrrole-3-carboxamide
863332-23-4P, 4-[5-(2,4-Dichlorophenyl)-2-methyl-3-[[(piperidin-1-yl)amino]carbonyl]-1H-pyrrol-1-yl]phenyl butane-1-sulfonate
863332-25-6P, 5-(2,4-Dichlorophenyl)-2-methyl-1-[4-(trimethylsilanyl)phenyl]-1H-pyrrole-3-carboxylic acid N-(piperidin-1-yl)amide 863332-26-7P, 4-[5-(2,4-Dichlorophenyl)-2-methyl-3-[[(piperidin-1-yl)amino]carbonyl]-1H-pyrrol-1-yl]phenyl propane-1-sulfonate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrrolecarboxamides for treatment of obesity and other diseases)

RN 863332-18-7 HCAPLUS
CN Methanesulfonic acid, trifluoro-, 4-[5-(2,4-dichlorophenyl)-2-methyl-3-[(1-piperidinylamino)carbonyl]-1H-pyrrol-1-yl]phenyl ester (9CI) (CA INDEX NAME)



RN 863332-22-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dichlorophenyl)-2-methyl-N-1-piperidinyl-1-[4-(3,3,3-trifluoropropoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 863332-23-4 HCAPLUS
CN 1-Butanesulfonic acid, 4-[5-(2,4-dichlorophenyl)-2-methyl-3-[(1-piperidinylamino)carbonyl]-1H-pyrrol-1-yl]phenyl ester (9CI) (CA INDEX NAME)



RN 863332-25-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dichlorophenyl)-2-methyl-N-1-piperidinyl-1-[4-(trimethylsilyl)phenyl]- (9CI) (CA INDEX NAME)



RN 863332-26-7 HCAPLUS
CN 1-Propanesulfonic acid, 4-[5-(2,4-dichlorophenyl)-2-methyl-3-[(1-piperidinylamino)carbonyl]-1H-pyrrol-1-yl]phenyl ester (9CI) (CA INDEX NAME)



IT 863332-17-6P, 5-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-2-methyl-N-(piperidin-1-yl)-1H-pyrrole-3-carboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolecarboxamides for treatment of obesity and other diseases)
RN 863332-17-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dichlorophenyl)-1-(4-hydroxyphenyl)-2-methyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 19 Aug 2005
GI



I

AB The invention provides pyrrole-containing compds. and methods of use thereof. Kits and pharmaceutical compns. comprising the pyrrole compds. of the invention are also provided. The compds. and compns. disclosed herein are preferably used in the treatment of neurodegenerative diseases, cardiovascular diseases, proliferative diseases, neuroinflammatory disorders, vascular disorders with an inflammatory component, and visual disorders. In particular, methods and compns. for the treatment of stroke are disclosed herein. Preparation of compds. of the invention, e.g. I, is included.

ACCESSION NUMBER: 2005:824494 HCAPLUS
DOCUMENT NUMBER: 143:206476
TITLE: Pyrrole compounds for use in the treatment of stroke and other conditions

02/08/2006,10540276.trn

INVENTOR(S): Lockhart, David J.; Patel, Hitesh K.; Milanov, Zdravko V.; Mehta, Shamal Anil; Zarrinkar, Patrick Parvis; Biggs, William H.; Ciceri, Pietro; Fabian, Miles A.; Treiber, Daniel Kelly
PATENT ASSIGNEE(S): Ambit Biosciences Corp., USA
SOURCE: U.S. Pat. Appl. Publ., 93 pp., Cont.-in-part of U.S. Ser. No. 848,584.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005182125	A1	20050818	US 2004-989995		20041115
US 2004259880	A1	20041223	US 2004-848584		20040518
PRIORITY APPLN. INFO.:			US 2003-471425P	P	20030516
			US 2003-480289P	P	20030620
			US 2003-480475P	P	20030620
			US 2003-488172P	P	20030716
			US 2003-488178P	P	20030716
			US 2003-516610P	P	20031030
			US 2003-516616P	P	20031030
			US 2003-516651P	P	20031030
			US 2004-848584	A2	20040518

OTHER SOURCE(S): MARPAT 143:206476
IT 811864-73-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrrole compds. for use in treatment of stroke and other conditions)
RN 811864-73-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-1-(4-methylphenyl)-N,4-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 Dec 2004
AB The invention provides pyrrole-containing compds. and methods of use thereof. Kits and pharmaceutical compns. comprising the pyrrole compds. of the invention are also provided. The compds. and compns. disclosed herein are preferably used in the treatment of neurodegenerative diseases, cardiovascular diseases, proliferative diseases, and visual disorders. In

particular, methods and compns. for the treatment of stroke are disclosed herein. The compds. described herein are useful in the treatment of various diseases; in particular diseases in which modulation of phosphodiesterase 6, quinone reductase 2, and/or calbindin-2 is desired.

ACCESSION NUMBER: 2004:1127333 HCAPLUS
DOCUMENT NUMBER: 142:69218
TITLE: Pyrrole compounds and uses thereof
INVENTOR(S): Lockhart, David J.; Patel, Hitesh K.; Milanov, Zdravko V.; Mehta, Shamal Anil; Zarrinkar, Patrick Parvis; Biggs, William H., III; Ciceri, Pietro; Fabian, Miles A.; Treiber, Daniel Kelly
PATENT ASSIGNEE(S): Ambit Biosciences Corporation, USA
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110998	A1	20041223	WO 2004-US15444	20040517
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004242673	A1	20041202	US 2004-847897	20040517
US 2004248972	A1	20041209	US 2004-848515	20040517
US 2004248957	A1	20041209	US 2004-848521	20040517
AU 2004247627	A1	20041223	AU 2004-247627	20040517
CA 2523808	AA	20041223	CA 2004-2523808	20040517
EP 1636183	A1	20060322	EP 2004-752457	20040517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.:

US 2003-471425P	P	20030516
US 2003-480289P	P	20030620
US 2003-480475P	P	20030620
US 2003-488172P	P	20030716
US 2003-488178P	P	20030716
US 2003-516610P	P	20031030
US 2003-516616P	P	20031030
US 2003-516651P	P	20031030
WO 2004-US15444	W	20040517

OTHER SOURCE(S): MARPAT 142:69218
IT 811864-73-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrrole compds. for disease treatment by modulation of phosphodiesterase 6 subunits and binding to GTPase and quinone reductase 2 and calbindin-2)
RN 811864-73-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-1-(4-methylphenyl)-N,4-diphenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 Nov 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. Q-L-Y-R1 [Q = Q1, H2NC(:NH); wherein R2 = NHNH2, NHNHBoc, (un)substituted NH2, morpholino, 4-acetyl-piperazinyl, 4-phenylpiperazinyl; R1 = each (un)substituted C1-16 alkyl, C2-8 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, carbocyclyl, carbocyclic alkyl, or heterocyclyl; L = each Q2-Q6 or its cis- or trans-isomer, Q7-Q16; R4 = H, C1-3 alkyl; R5 = H, each (un)substituted carbocyclic aryl or C1-3 alkyl; Y = SO2, CO, a single bond, CH2] or salts thereof are prepared These compds. are MCH receptor antagonists and used for regulating orphan G protein-coupled receptor SLC-1 and for the prevention and/or treatment of obesity, obesity-related diseases, anxiety, or depression. Thus, hydrogenolysis of benzyl cis-[[4-(4-dimethylaminoquinazolin-2-ylamino)cyclohexyl]methyl]carbamate over 5% Pd-C in MeOH at 50° under H atmospheric for 3 days gave a solution of cis-[[4-(4-dimethylaminoquinazolin-2-ylamino)cyclohexyl]methyl]amine in MeOH which underwent reductive alkylation with 4-bromo-2-trifluoromethoxybenzaldehyde and NaBH(OAc)3 in AcOH/CH2Cl2 to give, after purification using HPLC and treatment with 4 N HCl/EtOAc, compound (I).2HCl. In a high throughput function screen for identifying lead compds., I.2HCl inhibited the human MCH-induced cellular Ca2+ flux with IC50 of 6 μg/mL.

ACCESSION NUMBER: 2004:963181 HCAPLUS
DOCUMENT NUMBER: 141:379941
TITLE: Preparation of quinazoline-2,4-diamines as melanin concentrating hormone (MCH) receptor antagonists
INVENTOR(S): Sekiguchi, Yoshikatsu; Kanuma, Yukihiro; Omodera, Katsunori; Tran, Thuy-ahn; Kramer, Bryan Aubrey; Beeley, Nigel Robert Arnold
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 988 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004315511	A2	20041111	JP 2004-95046	20040329
PRIORITY APPLN. INFO.:			JP 2003-93418 A	20030331

OTHER SOURCE(S): MARPAT 141:379941
IT 509143-54-8P 510743-47-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as melanin-concentrating hormone (MCH) receptor
antagonists for prevention and/or treatment of obesity, obesity-related diseases, anxiety, or depression)
RN 509143-54-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[cis-4-[[4-(dimethylamino)-2-quinazolinyl]amino]cyclohexyl]-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 510743-47-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[[cis-4-[[4-(dimethylamino)-2-quinazolinyl]amino]cyclohexyl]methyl]-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 8 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 08 Oct 2004
GI



I



II



III



IV

AB Title compds. I, II, and III [wherein R1 = (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, aryl; R2 = H, halo, OH, carboxy, carbamoyl, amino, (un)substituted alkyl, alkoxy; T = independently H, halo, OH, carboxy, carbamoyl, amino, cyano, NO2, alkenyl, alkynyl, cycloalkyl, (un)substituted alkyl, alkoxy; p = 0-5; L = aminocycloalkylideneamino, etc.; Y = bond, CH2, CO2, OCO, SO2, CO, CS, CONH, CSNH, etc.; with provisos; and pharmaceutically acceptable salts, hydrates, or solvates thereof] were prepared as antagonists of melanin concentrating hormone (MCH), an endogenous ligand of G-protein coupled receptors (GPCRs). Examples include solution and solid phase general synthetic methods and phys. data for nearly 3400 invention compds. In addition, all exemplified compds. were assayed using high throughput functional screening to detect intracellular Ca2+ concns. for accessing GPCR activation. For instance, reaction of 2,4-dichloro-6-methylpyrimidine with dimethylamine gave 2-chloro-4-(dimethylamino)-6-methylpyrimidine (40%), which was coupled with cis-(4-aminocyclohexyl)carbamic acid tert-Bu ester (60%). Deprotection (72%), amidation, and workup provided the benzamide IV•TFA. The latter demonstrated MCH antagonist activity with an IC50 value of 7.6 nM. Thus, pharmaceutical compns. comprising I are useful for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders, and dyskinesias including Parkinson's disease, epilepsy, and addiction (no data). This is part I of three in a series covering the patent.

ACCESSION NUMBER: 2004:822842 HCAPLUS

DOCUMENT NUMBER: 141:314346
TITLE: Preparation of quinoline, tetrahydroquinazoline, and pyrimidine derivatives as MCH antagonist for treatment of CNS disorders
INVENTOR(S): Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han, Sangdon; Casper, Martin; Kramer, Bryan A.; Semple, Graeme; Zou, Ning
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co. Ltd., Japan; Arena Pharmaceuticals, Inc.
SOURCE: Eur. Pat. Appl., 586 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1464335	A2	20041006	EP 2004-7651	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 2005197350	A1	20050908	US 2004-812075	20040330
AU 2004226049	A1	20041014	AU 2004-226049	20040331
CA 2518913	AA	20041014	CA 2004-2518913	20040331
WO 2004087669	A1	20041014	WO 2004-JP4624	20040331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2004300156	A2	20041028	JP 2004-107965	20040331
BR 2004008910	A	20060321	BR 2004-8910	20040331
NO 2005004999	A	20051107	NO 2005-4999	20051027

PRIORITY APPLN. INFO.:			
US 2003-458530P	P	20030331
US 2003-495911P	P	20030819
US 2003-510186P	P	20031009
US 2003-530360P	P	20031216
WO 2004-JP4624	W	20040331

OTHER SOURCE(S): MARPAT 141:314346
IT 769183-15-5P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide
769184-55-6P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide
769185-93-5P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH antagonist; preparation of quinolines, quinazolines, and pyrimidines as MCH antagonist for treatment of CNS disorders)
RN 769183-15-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[cis-4-[[4-(dimethylamino)-2-

quinolinyl]amino]cyclohexyl]-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 769184-55-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[cis-4-[[4-(dimethylamino)-2-pyrimidinyl]amino]cyclohexyl]-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 769185-93-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydro-2-quinazolinyl]amino]cyclohexyl]-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 9 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 19 Aug 2004
AB A process for the preparation of a stable dispersion of solid particles, in an aqueous medium comprises combining a first solution comprising a substantially water-insol. pyrrolecarboxamide, a water-miscible organic solvent and an inhibitor with an aqueous phase comprising water and optionally a stabilizer.

The solid particles comprising the inhibitor and the water-insol. substance are precipitated and he water-miscible organic solvent is removed. Also claimed are stable dispersions obtainable by the process, solid particles obtainable by the process and the use of such particles. The process provides a dispersion of solid particles in an aqueous medium, which particles exhibit reduced or substantially no particle growth mediated by Ostwald ripening. The process is particularly suitable for the preparation of small (sub-micron) aqueous dispersions of a substantially water-insol. active substance. Thus, a solution of 1-{[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-1H-pyrrol-3-yl]carbonyl}piperidine (90 mM) and 10.0 mg/mL Miglyol 812N in dimethylacetamide was prepared and 0.1 mL this solution was added rapidly to an 0.8-mL aqueous solution containing 0.2% polyvinylpyrrolidone and 0.25 mM sodium dodecyl sulfate. The aqueous solution was sonicated during the addition of the organic solution This resulted in the precipitation of particles with a mean size of 126 nm. No increase in particle size was observed over a period of 2 h at 20°. The synthesis of pyrrolecarboxamides is given.

ACCESSION NUMBER: 2004:675653 HCAPLUS
DOCUMENT NUMBER: 141:195288
TITLE: Aqueous dispersions comprising stable nanoparticles of a water-insoluble pyrrolecarboxamide and medium-chain triglyceride excipients
INVENTOR(S): Lindfors, Lennart
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069227	A1	20040819	WO 2004-GB402	20040202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1592404	A1	20051109	EP 2004-707263	20040202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: GB 2003-2671 A 20030206
WO 2004-GB402 W 20040202

OTHER SOURCE(S): MARPAT 141:195288
IT 723303-38-6P 723303-39-7P 723303-40-0P
723303-41-1P 723303-42-2P 723303-43-3P
723303-44-4P 723303-45-5P 723303-46-6P
723303-47-7P 723303-49-9P 723303-51-3P
723303-53-5P 723303-55-7P 723303-57-9P
723303-60-4P 723303-62-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(aqueous dispersions comprising stable nanoparticles of water-insol. pyrrolecarboxamide and medium-chain triglyceride excipients)

RN 723303-38-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-methyl-N,1,5-triphenyl- (9CI) (CA INDEX NAME)



RN 723303-39-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-2-methyl-N,5-diphenyl- (9CI) (CA INDEX NAME)



RN 723303-40-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-methoxyphenyl)-2-methyl-N,5-diphenyl- (9CI) (CA INDEX NAME)



RN 723303-41-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dichlorophenyl)-2-methyl-N,1-diphenyl- (9CI) (CA INDEX NAME)



RN 723303-42-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 723303-43-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 723303-44-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dimethoxyphenyl)-2-methyl-N,1-diphenyl- (9CI) (CA INDEX NAME)



RN 723303-45-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 723303-46-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 723303-47-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-methyl-1,5-diphenyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-49-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-2-methyl-5-phenyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-51-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-methoxyphenyl)-2-methyl-5-phenyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-53-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dichlorophenyl)-2-methyl-1-phenyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-55-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-57-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-60-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-62-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 23 Jul 2004
GI



I



II

AB The invention relates to a preparation of novel 2-(thiazol-4-yl)pyrrole derivs. of formula I [wherein: R1 is H or alkyl; R2 is H, alkyl, alkenyl, or alkoxy-alkyl, etc.; R3 is alkyl, alkenyl, alkoxy-alkyl, or di-phenyl-alkyl, etc.; R4 is (un)substituted (cyclo)alkyl, alkoxycarbonyl, or 5- or 6-membered heterocycle; R5 and R6 are independently selected from

H, alkyl, halogen, or fluorinated methyl; R7 is H, alkyl, or halogen], useful as CB1 receptor antagonists. The invention compds. are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors. For instance, 2-(thiazol-4-yl)pyrrole derivative II (IC50 < 2 μM) was prepared using aminomethylcyclohexane, butylamine, and 2-chlorothiobenzamide (no yield data, example 7).

ACCESSION NUMBER: 2004:589547 HCAPLUS
DOCUMENT NUMBER: 141:140427
TITLE: A preparation of novel 2-(thiazol-4-yl)pyrrole derivatives, useful as CB1 receptor antagonists
INVENTOR(S): Guba, Wolfgang; Haap, Wolfgang; Marty, Hans Peter; Narquizian, Robert
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 235 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060888	A1	20040722	WO 2003-EP14721	20031222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2511905	AA	20040722	CA 2003-2511905	20031222
AU 2003293968	A1	20040729	AU 2003-293968	20031222
US 2004147572	A1	20040729	US 2003-743403	20031222
EP 1583762	A1	20051012	EP 2003-789381	20031222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017931	A	20051129	BR 2003-17931	20031222
CN 1735611	A	20060215	CN 2003-80108269	20031222
JP 2006513226	T2	20060420	JP 2004-564211	20031222

PRIORITY APPLN. INFO.: EP 2003-2 A 20030102
WO 2003-EP14721 W 20031222

OTHER SOURCE(S): MARPAT 141:140427
IT 726179-20-0P 726179-42-6P 726179-98-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel thiazolylpyrrole derivs., useful as CB1 receptor antagonists)
RN 726179-20-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(4-chlorophenyl)-5-[2-(4-methoxyphenyl)-4-thiazolyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 726179-42-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(2,3-dihydro-1H-inden-2-yl)-5-[2-(4-methoxyphenyl)-4-thiazolyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 726179-98-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-cyclohexyl-N-(cyclopropylmethyl)-5-[2-(4-methoxyphenyl)-4-thiazolyl]-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 15 Jul 2004
GI



I

AB Title compds. I [wherein R1, R2 = independently (un)substituted Ph, thienyl, pyridyl; R3 = H, (amino)alkyl, alkoxymethyl, trifluoromethyl, etc.; R4, R5 = independently (un)substituted (amino)alkyl, non-aromatic carbocyclic, cycloalkylalkyl, etc.; R6 = H, (hydroxy)alkyl, alkoxymethyl, carbamoyl, etc.; with proviso; X = CO or SO2; Y = absent or (un)substituted alkyl; and pharmaceutically acceptable salts, prodrugs and solvates thereof] were prepared as cannabinoid 1 (CB1) receptor modulators. For example, reaction of 2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxylic acid with aniline gave 2-methyl-N,1,5-triphenyl-1H-pyrrole-3-carboxamide in 52% yield. I are active at the CB1 receptor (IC50 <1 micromolar), most preferred compds. have IC50 <200 nanomolar. Thus, I and their pharmaceutical compns. are useful for the treatment of obesity, psychiatric and neurol. disorders (no data).

ACCESSION NUMBER: 2004:565082 HCAPLUS
DOCUMENT NUMBER: 141:123553
TITLE: Preparation of 1,5-diaryl-pyrrole-3-carboxamide derivatives as cannabinoid receptor modulators
INVENTOR(S): Berggren, Anna Ingrid Kristina; Bostrom, Stig Jonas; Cheng, Leifeng; Elebring, Stig Thomas; Greasley, Peter; Nagard, Mats; Wilstermann, Johan Michael; Terricabras, Emma
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058249	A1	20040715	WO 2003-GB5569	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2511601	AA	20040715	CA 2003-2511601	20031218
AU 2003290292	A1	20040722	AU 2003-290292	20031218
EP 1578417	A1	20050928	EP 2003-782654	20031218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017705	A	20051122	BR 2003-17705	20031218
CN 1753668	A	20060329	CN 2003-80109972	20031218
JP 2006513201	T2	20060420	JP 2004-563346	20031218
NO 2005002995	A	20050722	NO 2005-2995	20050617
US 2006122230	A1	20060608	US 2005-540276	20050621

PRIORITY APPLN. INFO.: GB 2002-30088 A 20021224
WO 2003-GB5569 W 20031218

OTHER SOURCE(S): MARPAT 141:123553
IT 723303-38-6P 723303-39-7P 723303-40-0P
723303-41-1P 723303-42-2P 723303-43-3P
723303-44-4P 723303-45-5P 723303-46-6P
723303-47-7P 723303-49-9P 723303-51-3P
723303-53-5P 723303-55-7P 723303-57-9P
723303-60-4P 723303-62-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,5-diaryl-pyrrole-3-carboxamide derivs. as CB1 modulators)

RN 723303-38-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-methyl-N,1,5-triphenyl- (9CI) (CA INDEX NAME)



RN 723303-39-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-2-methyl-N,5-diphenyl- (9CI)

(CA INDEX NAME)



RN 723303-40-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-methoxyphenyl)-2-methyl-N,5-diphenyl- (9CI) (CA INDEX NAME)



RN 723303-41-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dichlorophenyl)-2-methyl-N,1-diphenyl- (9CI) (CA INDEX NAME)



RN 723303-42-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 723303-43-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 723303-44-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dimethoxyphenyl)-2-methyl-N,1-diphenyl- (9CI) (CA INDEX NAME)



RN 723303-45-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 723303-46-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 723303-47-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-methyl-1,5-diphenyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-49-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-2-methyl-5-phenyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-51-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-methoxyphenyl)-2-methyl-5-phenyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-53-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dichlorophenyl)-2-methyl-1-phenyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-55-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-57-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-60-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 723303-62-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-N-1-piperidinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 11 Apr 2003
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. QLYR1[Q = I, C(:NH)NH2; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, etc.; L = II-IV (wherein R4 = H, alkyl; R5 = H, alkyl, alkyl substituted by a substituted carbocyclic aryl), etc.; Y = SO2, CO, (CH2)m; m = 0-1] which act as MCH receptor antagonists, and are useful for prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression, were prepared Thus, hydrogenation of benzyl cis-[4-(4-dimethylaminoquinazolin-2-ylamino)cyclohexylmethyl]carbamate followed by reacting the resulting intermediate with 4-bromo-2-trifluoromethoxybenzaldehyde in the presence of NaBH(OAc)3 and AcOH in CH2Cl2, and treatment of the product with 4N HCl in EtOAc afforded 34% cis-V.2HCl which showed IC50 of 6 nM against MCH receptor.

ACCESSION NUMBER: 2003:282325 HCAPLUS
DOCUMENT NUMBER: 138:321285
TITLE: Preparation of quinazoline-2,4-diamines as MCH receptor antagonists
INVENTOR(S): Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Tran, Thuy-anh; Kramer, Bryan Aubrey; Beeley, Nigel Robert Arnold
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 1171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003028641 A2 20030410 WO 2002-US31059 20020930
WO 2003028641 A3 20030828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2460594 AA 20030410 CA 2002-2460594 20020930
EP 1432693 A2 20040630 EP 2002-800388 20020930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
CN 1582281 A 20050216 CN 2002-823940 20020930
JP 2005523237 T2 20050804 JP 2003-531977 20020930
PRIORITY APPLN. INFO.: US 2001-326463P P 20011001
US 2001-326758P P 20011002
WO 2002-US31059 W 20020930

OTHER SOURCE(S): MARPAT 138:321285
IT 509143-54-8P 510743-47-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline-2,4-diamines as MCH receptor antagonists)
RN 509143-54-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[cis-4-[[4-(dimethylamino)-2-quinazolinyl]amino]cyclohexyl]-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 510743-47-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[[cis-4-[[4-(dimethylamino)-2-quinazolinyl]amino]cyclohexyl]methyl]-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 13 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Apr 2003
GI



I

AB This invention relates to pyrrolecarboxamides and pyrrolecarbohydrazides (shown as I; variables defined below; e.g. 1-(2-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-N-(1-piperidinyl)-1H-pyrrole-3-carboxamide hydrochloride) that suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compds., pharmaceutical compns. comprising the compds., and methods of using such compns. for inducing weight loss and treating obesity and obesity-related disorders. Although the methods of preparation are not claimed, 6 example prepns. of I and/or intermediates and characterization data for .apprx.50 examples of I are included. Seven pharmaceutical formulations are listed. Compds. of this invention are active in a fasted-refed acute feeding assay. For example, when 1-(2-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-N-(1-piperidinyl)-1H-pyrrole-3-carboxamide hydrochloride was dosed at 10 mg/kg p.o., food consumption was reduced (relative to the food consumption observed for the vehicle control group) by up to 25% when measured at time points = 30-240 min. Likewise, when 1-(2-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dimethyl-N'-[4-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbohydrazide hydrochloride was dosed at 10 mg/kg p.o., food consumption was reduced by up to 35%. For I: R1 and R2 = Ph optionally substituted with ≥1 halogen, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl, hydroxy, cyano, or nitro; R3 = H; R4 = CH3; R5 = H or (C1-C6)alkyl; R6 = substituted cyclohexyl; (un)substituted (C1-C5)alkyl; cyclopentyl, cycloheptyl or cyclo(C3-C7)alkyl-(C1-C3)alkyl, each of which may be optionally substituted; substituted benzyl; substituted phenyl; piperidin-4-yl, piperidin-3-yl, or pyrrolidin-3-yl, each of which may be optionally substituted on the N atom of the piperidine or pyrrolidine ring; -NR7R8. Or R5 and R6, taken together with the N atom to which they are attached, form a 5- to 10-membered saturated heterocyclic radical containing at least one addnl. N atom, with optional substitution. Or R5 and R6, taken together with the N atom to which they are attached, form a 1-piperidinyl, 1-pyrrolidinyl, or 1-morpholino group, which is substituted; addnl. details are given in the claims.
ACCESSION NUMBER: 2003:261810 HCAPLUS

DOCUMENT NUMBER: 138:287520
TITLE: Preparation and use of pyrrolecarboxamides and pyrrolecarbohydrazides for treating obesity
INVENTOR(S): Smith, Roger A.; Kluender, Harold C. E.; Su, Ning; Lavoie, Rico C.; Fan, Jianmei
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003027069	A1	20030403	WO 2002-US30543		20020924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2461144	AA	20030403	CA 2002-2461144		20020924
EP 1432679	A1	20040630	EP 2002-799637		20020924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 2005532982	T2	20051104	JP 2003-530660		20020924
US 2004267028	A1	20041230	US 2004-489031		20040305
PRIORITY APPLN. INFO.:			US 2001-324441P	P	20010924
			WO 2002-US30543	W	20020924

OTHER SOURCE(S): MARPAT 138:287520
IT 504405-88-3P, 2-Amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-cyclohexyl-1H-pyrrole-3-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation and use of pyrrolecarboxamides for treating obesity)
RN 504405-88-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-cyclohexyl- (9CI) (CA INDEX NAME)



IT 118179-43-4P, N-Cyclohexyl-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-37-2P, N-Cyclohexyl-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide 504405-38-3P, N-(4-Methylcyclohexyl)-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide 504405-39-4P, N-(Cyclohexylmethyl)-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide 504405-40-7P, 1-(2-Chlorophenyl)-5-(4-methoxyphenyl)-2-methyl-N-(1-piperidinyl)-1H-pyrrole-3-carboxamide hydrochloride 504405-42-9P, N-Cyclohexyl-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-44-1P, 1-(2-Chlorophenyl)-5-(4-methoxyphenyl)-2-methyl-N'-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbohydrazide hydrochloride 504405-45-2P, N'-(3-(Trifluoromethyl)phenyl)-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-2-methyl-1H-pyrrole-3-carbohydrazide hydrochloride 504405-46-3P, N'-(4-(Trifluoromethyl)phenyl)-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-2-methyl-1H-pyrrole-3-carbohydrazide hydrochloride 504405-52-1P, N-(trans-2-(Benzyloxy)cyclohexyl)-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-53-2P, N-(Piperidino)-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide hydrochloride 504405-54-3P, N'-(2-(Trifluoromethyl)phenyl)-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carbohydrazide hydrochloride 504405-55-4P, N'-(4-(Trifluoromethyl)phenyl)-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carbohydrazide hydrochloride 504405-56-5P, N-(trans-2-Hydroxycyclohexyl)-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-57-6P, 5-(4-Chlorophenyl)-1-(2;4-dichlorophenyl)-N-(cis-2-hydroxycyclohexyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-58-7P, N-(trans-2-(Benzyloxy)cyclohexyl)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-59-8P, 1-(2-Chlorophenyl)-5-(4-chlorophenyl)-2-methyl-N-(1-piperidinyl)-1H-pyrrole-3-carboxamide hydrochloride 504405-61-2P , N-Cyclohexyl-1-(2-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-62-3P, 1-(2-Chlorophenyl)-5-(4-chlorophenyl)-2-methyl-N'-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbohydrazide hydrochloride 504405-64-5P, N'-(4-(Trifluoromethyl)phenyl)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carbohydrazide hydrochloride 504405-65-6P, 1-(2-Chlorophenyl)-5-(4-chlorophenyl)-N-(trans-2-hydroxycyclohexyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-66-7P, N-(cis-2-Hydroxycyclohexyl)-1-(2-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-67-8P, N-((4-Chlorophenyl)methyl)-1-(2,4-dichlorophenyl)-5-

(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-68-9P, N-((4-Fluorophenyl)methyl)-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-69-0P, N-((4-(Trifluoromethyl)phenyl)methyl)-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-70-3P, N-(4-Fluorophenyl)-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-71-4P, N-(1-Benzylpiperidin-4-yl)-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-80-5P, N-Cyclohexyl-1-(2-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide 504405-81-6P, 1-(2-Chlorophenyl)-5-(4-methoxyphenyl)-2,4-dimethyl-N'-[4-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbohydrazide hydrochloride 504405-82-7P, 2-Amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-cyclohexyl-1H-pyrrole-3-carboxamide hydrochloride 504405-83-8P, 2-Amino-1-phenyl-5-(4-chlorophenyl)-N-cyclohexyl-1H-pyrrole-3-carboxamide hydrochloride 504405-84-9P, 2-Amino-1-(2-fluorophenyl)-5-(4-chlorophenyl)-N-cyclohexyl-1H-pyrrole-3-carboxamide hydrochloride 504405-85-0P, 2-Amino-1-(2-bromophenyl)-5-(4-chlorophenyl)-N-cyclohexyl-1H-pyrrole-3-carboxamide hydrochloride 504405-86-1P, 2-Amino-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-N-cyclohexyl-1H-pyrrole-3-carboxamide hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation and use of pyrrolecarboxamides for treating obesity-related disorders)

RN 118179-43-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-N-cyclohexyl-1-(2,4-dichlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 504405-37-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclohexyl-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)



RN 504405-38-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-methyl-N-(4-methylcyclohexyl)-1,5-diphenyl-(9CI) (CA INDEX NAME)



RN 504405-39-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(cyclohexylmethyl)-2-methyl-1,5-diphenyl-(9CI) (CA INDEX NAME)



RN 504405-40-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2-chlorophenyl)-5-(4-methoxyphenyl)-2-methyl-N-1-piperidinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 504405-42-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2-chlorophenyl)-N-cyclohexyl-5-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 504405-44-1 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(2-chlorophenyl)-5-(4-methoxyphenyl)-2-methyl-, 2-[2-(trifluoromethyl)phenyl]hydrazide, hydrochloride (9CI) (CA INDEX NAME)



RN 504405-45-2 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(2-chlorophenyl)-5-(4-methoxyphenyl)-2-methyl-, 2-[3-(trifluoromethyl)phenyl]hydrazide, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 504405-46-3 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(2-chlorophenyl)-5-(4-methoxyphenyl)-2-methyl-, 2-[4-(trifluoromethyl)phenyl]hydrazide, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 504405-52-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-2-methyl-N-[(1R,2R)-2-(phenylmethoxy)cyclohexyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 504405-53-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-2-methyl-N-1-piperidinyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 504405-54-3 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-2-methyl-, 2-[2-(trifluoromethyl)phenyl]hydrazide, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 504405-55-4 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-2-methyl-, 2-[4-(trifluoromethyl)phenyl]hydrazide, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 504405-56-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-[(1R,2R)-2-hydroxycyclohexyl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 504405-57-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-[(1R,2S)-2-hydroxycyclohexyl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 504405-58-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-N-[(1R,2R)-2-(phenylmethoxy)cyclohexyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 504405-59-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-N-1-piperidinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 504405-61-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-cyclohexyl-2-methyl- (9CI) (CA INDEX NAME)



RN 504405-62-3 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-, 2-[2-(trifluoromethyl)phenyl]hydrazide, hydrochloride (9CI) (CA INDEX NAME)



RN 504405-64-5 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-, 2-[4-(trifluoromethyl)phenyl]hydrazide, hydrochloride (9CI) (CA INDEX NAME)



RN 504405-65-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-[(1R,2R)-2-hydroxycyclohexyl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 504405-66-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-[(1R,2S)-2-hydroxycyclohexyl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 504405-67-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-N-[(4-chlorophenyl)methyl]-1-(2,4-dichlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 504405-68-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 504405-69-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-2-methyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 504405-70-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 504405-71-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-2-methyl-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 504405-80-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2-chlorophenyl)-N-cyclohexyl-5-(4-methoxyphenyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 504405-81-6 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 1-(2-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dimethyl-, 2-[4-(trifluoromethyl)phenyl]hydrazide, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 504405-82-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-amino-1-(2-chlorophenyl)-5-(4-chlorophenyl)-N-cyclohexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 504405-83-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-amino-5-(4-chlorophenyl)-N-cyclohexyl-1-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 504405-84-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-amino-5-(4-chlorophenyl)-N-cyclohexyl-1-(2-fluorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 504405-85-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-amino-1-(2-bromophenyl)-5-(4-chlorophenyl)-N-cyclohexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 504405-86-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-amino-5-(4-chlorophenyl)-N-cyclohexyl-1-(2,4-dichlorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 15 Nov 2002
GI



I



II

AB The title compds. [I; Ar = (un)substituted Ph, pyridyl, thienyl, etc.; A = (un)substituted Ph, thienyl, furanyl, etc.; Y = O, NH, CONHCH2, SOn, CH2, a bond; R2 = H, halo, CF3, CN, alkyl; R1, R3, R4 = H, alkyl, CH2Ph; X = O, S, CH2; n = 0-2], useful as antagonists of urotensin II, were prepared and formulated. E.g., a 6-step synthesis of (R)-II, starting from 2-chloro-5-nitroanisole, was given. Activity for the compds. I against h-U-II range from Ki = 10-10000 nM.

ACCESSION NUMBER: 2002:868728 HCAPLUS
DOCUMENT NUMBER: 137:370085
TITLE: Preparation of sulfonamides as antagonists of urotensin II

INVENTOR(S): Dhanak, Dashyant; Gallagher, Timothy F.; Knight, Steven D.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002089793	A1	20021114	WO 2002-US14409	20020507
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1387679	A1	20040211	EP 2002-769373	20020507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004529164	T2	20040924	JP 2002-586928	20020507
US 2004198979	A1	20041007	US 2003-477051	20031107
PRIORITY APPLN. INFO.:			US 2001-289305P	P 20010507
			US 2001-289307P	P 20010507
			WO 2002-US14409	W 20020507

OTHER SOURCE(S): MARPAT 137:370085
IT 474947-42-7P 474947-44-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides as antagonists of urotensin II)
RN 474947-42-7 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-[[[4-chloro-3-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]sulfonyl]-2-(4-chlorophenyl)-5-methyl-1-phenyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474947-44-9 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 4-[[[4-chloro-3-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]sulfonyl]-5-methyl-1,2-diphenyl-, ethyl

ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 01 Jul 1999
AB The calcn. of possible mol. formulas on the basis of the very precise ESI-FT-ICR measurement thus gave solely the correct composition This rapid mol. formula determination may also be applied to complex mixts. such as those which arise from combinatorial chemical To demonstrate the performance of this method in this respect, a split-mix compound collection of 140 different pyrrole amides consisting of 10 subcollections of 14 compds. each was synthesized on Rink amide AM resin. The results of the subcollection with 2-bromoacetophenone as building block (R2=C6H5, R3=H) are illustrated as an example. The total amount of sample of 20 pmol gives a mean sample consumption of 1.4 pmol per compound for the routine measurement. All 14 expected products could be detected by mass spectrometry.
ACCESSION NUMBER: 1999:404464 HCAPLUS
DOCUMENT NUMBER: 131:193473
TITLE: ESI Fourier transform ion cyclotron resonance mass spectrometry (ESI-FT-ICR-MS): a rapid high-resolution analytical method for combinatorial compound libraries
AUTHOR(S): Walk, Tilmann B.; Trautwein, Axel W.; Richter, Hartmut; Jung, Gunther
CORPORATE SOURCE: Institut fur Organische Chemie der Universitat, Tubingen, D-72076, Germany
SOURCE: Angewandte Chemie, International Edition (1999), 38(12), 1763-1765
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 239474-84-1 239474-93-2 239474-97-6
RL: ANT (Analyte); PEP (Physical, engineering or chemical process); ANST (Analytical study); PROC (Process)
(ESI Fourier transform ion cyclotron resonance mass spectrometry for rapid high-resolution anal. of combinatorial compds. of)
RN 239474-84-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-cyclopropyl-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 239474-93-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,3-dihydro-1H-inden-1-yl)-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 239474-97-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-methyl-5-phenyl-1-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 28 Feb 1996
AB A number of new title compds. (6) have been synthesized by the reaction of N-methyl/N,N-diethylacetoacetamide with benzoin and various alkyl, aryl and aralkylamines in the presence of formic acid. Compds. 6 showed appreciable antifungal activity mild bactericidal activity.
ACCESSION NUMBER: 1996:122149 HCAPLUS
DOCUMENT NUMBER: 124:289156
TITLE: Synthesis of some new 4,5-diphenyl-3-(N-methyl/N,N-diethyl)carbamoyl-2-methyl-1-substituted-1H-pyrroles and their fungicidal activity
AUTHOR(S): Sadanandam, Y. S.; Leelavathi, P.; Shetty, Meera M.

CORPORATE SOURCE: Organic Chemistry Division-I, Indian Institute Chemical Technology, Hyderabad, 500 007, India
SOURCE: Indian Journal of Heterocyclic Chemistry (1995), 5(2), 125-8
CODEN: IJCHEI; ISSN: 0971-1627
PUBLISHER: Lucknow University, Dep. of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 175475-93-1P 175475-94-2P 175475-95-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antimicrobial activity of)

RN 175475-93-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N,2-dimethyl-1,4,5-triphenyl- (9CI) (CA INDEX NAME)



RN 175475-94-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N,2-dimethyl-1-(4-methylphenyl)-4,5-diphenyl- (9CI) (CA INDEX NAME)



RN 175475-95-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N,2-dimethyl-4,5-diphenyl- (9CI) (CA INDEX NAME)



IT 175475-96-4P 175475-97-5P 175475-98-6P
175475-99-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 175475-96-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-methoxyphenyl)-N,2-dimethyl-4,5-diphenyl-
(9CI) (CA INDEX NAME)



RN 175475-97-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N,2-dimethyl-1-(2-nitrophenyl)-4,5-diphenyl-
(9CI) (CA INDEX NAME)



RN 175475-98-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N,2-dimethyl-1-(4-nitrophenyl)-4,5-diphenyl-(9CI) (CA INDEX NAME)



RN 175475-99-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,4-dichlorophenyl)-N,2-dimethyl-4,5-diphenyl-(9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 15 Feb 1996
AB Several fused pyrimidinones were synthesized by reaction of aminoarenecarboxamide with esters in moderate to good yields. In the presence of sodium ethoxide, treatments of 2-amino-1-phenyl-3-pyrrolecarboxamide, 2-amino-3-thiophenecarboxamide, 3-amino-4-isoxazolecarboxamide, 4-amino-1,2,3-triazole-5-carboxamide, and o-aminobenzamide with esters such as Et formate and Et acetate led to the corresponding pyrrolo[2,3-d]- and thieno[2,3-d]pyrimidin-4(3H)-ones, isoxazolo[5,4-d]pyrimidin-4(5H)-ones, 1,2,3-triazolo[4,5-d]pyrimidin-7(6H)-ones, and -4(3H)-quinazolones, resp.
ACCESSION NUMBER: 1996:97030 HCAPLUS
DOCUMENT NUMBER: 124:260966
TITLE: Synthesis of fused pyrimidinones by reaction of aminoarenecarboxamide with esters; preparation of pyrrolo[2,3-d]-, thieno[2,3-d]-, isoxazolo[5,4-d]-,

and 1,2,3-triazolo[4,5-d]pyrimidinones, and -quinazolones
AUTHOR(S): Miyashita, Akira; Fujimoto, Katsuhiro; Okada, Tomomi; Higashino, Takeo
CORPORATE SOURCE: Sch. Pharm. Sci., Univ. Shizuoka, Shizuoka, 422, Japan
SOURCE: Heterocycles (1996), 42(2), 691-9
CODEN: HTCYAM; ISSN: 0385-5414
PUBLISHER: Japan Institute of Heterocyclic Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 56023-01-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of fused pyrimidinones by reaction of aminoarenecarboxamide with esters)
RN 56023-01-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-amino-1,4,5-triphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 30 Mar 1993
GI



I

AB The synthesis and anti-Candida activity of some 3-aminomethyl-1,5-diaryl-2-methylpyrroles, e.g., I (R = H, 4-Cl, 4-F, 2,4-Cl2; R1 = H, Cl; R2 = NMe2, NHPh, pyrrolidino, 1-imidazolyl, 4-methylpiperazin-1-yl) are reported. Some derivs. show a rather strong anti-Candida activity. On the basis of exptl. results, microbiol. activity of 1,5-diarylpyrroles appears to be mainly related to aminic nitrogen lone pair availability of C3 substituent of the pyrrole nucleus. The C5 and N1 substituents play an important role in modulating biol. activity. Some structure-activity relationships are proposed.
ACCESSION NUMBER: 1993:124338 HCAPLUS
DOCUMENT NUMBER: 118:124338
TITLE: Studies on anti-Candida agents with a pyrrole moiety. Synthesis and microbiological activity of some

3-(aminomethyl)-1,5-diaryl-2-methylpyrrole derivatives
AUTHOR(S): Cerreto, F.; Villa, A.; Retico, A.; Scalzo, M.
CORPORATE SOURCE: Dip. Studi Chim. Technol. Sostanze Biol. Attive, Univ. La Sapienza, Rome, 00185, Italy
SOURCE: European Journal of Medicinal Chemistry (1992), 27(7), 701-8
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 146204-80-0P 146204-81-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antifungal activity of)
RN 146204-80-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1,5-bis(4-chlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 146204-81-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1,5-bis(4-chlorophenyl)-N,N,2-trimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 30 Mar 1993
AB The synthesis of some [(1-alkyl), (1-aryl) and (1-benzyl)-5-aryl-3-

carboxamido-2-methyl]pyrrole derivs. is reported. Their activity against Candida strains was assessed and the structure-activity relationships for these compds. are discussed and related to structure-activity guidelines proposed for a series of previously studied 1,5-diarylpyrroles.

ACCESSION NUMBER: 1993:120801 HCAPLUS
DOCUMENT NUMBER: 118:120801
TITLE: Studies on anti-Candida agents with a pyrrole moiety. Synthesis and microbiological activity of some [(1-alkyl),(1-aryl) and (1-benzyl)-5-aryl-3-carboxamido-2-methyl]pyrrole derivatives
AUTHOR(S): Scalzo, Marcello; Biava, Mariangela; Cerreto, Felice; Villa, Adelaide
CORPORATE SOURCE: Dip. Studi Chim. Tecnol., Univ. "La Sapienza", Rome, Italy
SOURCE: Farmaco (1992), 47(7-8), 1047-53
CODEN: FRMCE8; ISSN: 0014-827X
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 146429-89-2P 146429-90-5P 146429-91-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and fungicidal activity of)

RN 146429-89-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2-chlorophenyl)-N,N-bis(2-hydroxyethyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 146429-90-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N,N-bis(2-hydroxyethyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 146429-91-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N,N-bis(2-hydroxyethyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 Jan 1992
AB The correlation between lipophilicity and activity against Candida albicans of some 1,5-diarylpyrroles is described.
ACCESSION NUMBER: 1992:18272 HCAPLUS
DOCUMENT NUMBER: 116:18272
TITLE: Correlation analysis in a set of 1,5-diarylpyrroles with antimycotic activity
AUTHOR(S): Scalzo, M.; Biava, M.; Porretta, G. C.; Cerreto, F.
CORPORATE SOURCE: Fac. Farm., Univ. "La Sapienza", Rome, Italy
SOURCE: Pharmacochemistry Library (1991), 16(QSAR: Ration. Approaches Des. Bioact. Compd.), 389-92
CODEN: PHLIDQ; ISSN: 0165-7208
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 138147-74-7D, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antimycotic activity of, QSAR of)
RN 138147-74-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 16 Sep 1989
AB A series of 1,5-diarylpyrrole derivs. were synthesized and tested in vitro for their activity against bacteria and fungi. Forty-eight derivs. were evaluated for their antifungal activity against Candida albicans and various strains of Candida species. The antibacterial activity of 10 derivs. was evaluated against gram-pos. and gram-neg. bacteria. Structure-activity relations are discussed.
ACCESSION NUMBER: 1989:493768 HCAPLUS
DOCUMENT NUMBER: 111:93768
TITLE: Synthesis and microbiological activity of new 1,5-diarylpyrroles
AUTHOR(S): Scalzo, Marcello; Biava, Mariangela; Cerreto, Felice; Porretta, Giulo Cesare; Panico, Salvatore; Simonetti, Nicola
CORPORATE SOURCE: Fac. Farm., Univ. La Sapienza, Rome, Italy
SOURCE: European Journal of Medicinal Chemistry (1988), 23(6), 587-91
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 111:93768
IT 122121-42-0P 122121-43-1P 122121-44-2P
122121-45-3P 122121-47-5P 122121-48-6P
122121-49-7P 122121-50-0P 122121-52-2P
122121-53-3P 122121-54-4P 122121-55-5P
122121-57-7P 122121-58-8P 122121-59-9P
122121-60-2P 122121-62-4P 122121-63-5P
122121-64-6P 122121-65-7P 122121-67-9P
122121-68-0P 122121-69-1P 122121-70-4P
122121-71-5P 122121-72-6P 122121-73-7P
122148-64-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antimicrobial activity of)
RN 122121-42-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-fluorophenyl)-N-hexyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-43-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-dodecyl-1-(4-fluorophenyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-44-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-fluorophenyl)-2-methyl-5-(4-nitrophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 122121-45-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[(4-chlorophenyl)methyl]-1-(4-fluorophenyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-47-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-bromophenyl)-N-hexyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-48-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-bromophenyl)-N-dodecyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-49-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-bromophenyl)-2-methyl-5-(4-nitrophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 122121-50-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-bromophenyl)-N-[(4-chlorophenyl)methyl]-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-52-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-hexyl-2-methyl-5-(4-nitrophenyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 122121-53-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-dodecyl-2-methyl-5-(4-nitrophenyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 122121-54-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-methyl-5-(4-nitrophenyl)-N-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 122121-55-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(4-chlorophenyl)methyl]-2-methyl-5-(4-nitrophenyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 122121-57-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[2-chloro-5-(trifluoromethyl)phenyl]-N-hexyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-58-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[2-chloro-5-(trifluoromethyl)phenyl]-N-dodecyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-59-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-[2-chloro-5-(trifluoromethyl)phenyl]-2-methyl-5-(4-nitrophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 122121-60-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(4-chlorophenyl)methyl]-1-[2-chloro-5-(trifluoromethyl)phenyl]-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-62-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,5-dichlorophenyl)-N-hexyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-63-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,5-dichlorophenyl)-N-dodecyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-64-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,5-dichlorophenyl)-2-methyl-5-(4-nitrophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 122121-65-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(4-chlorophenyl)methyl]-1-(3,5-dichlorophenyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-67-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,4-dichlorophenyl)-N-hexyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-68-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,4-dichlorophenyl)-N-dodecyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-69-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,4-dichlorophenyl)-2-methyl-5-(4-nitrophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 122121-70-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(4-chlorophenyl)methyl]-1-(3,4-dichlorophenyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-71-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-72-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-2-methyl-5-(4-nitrophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 122121-73-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(4-chlorophenyl)methyl]-1-(2,4-dichlorophenyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122148-64-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-hexyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Feb 1989
GI



I

AB The synthesis and antifungal activities of new 1,5-diarylpyrrole derivs. I (R = NO2, Cl; R1 = HNC6H11, HNC12H25, HNC6H13, N-methylpiperazinyl; R2 = H, NO2; n = 1 or 2) are reported. In comparison with pyrrolnitrin, only carboxamide derivs. exhibit satisfactory antifungal activity. All the compds. show very poor antibacterial activity. The displacement of the NO2 group from the para to the meta or ortho positions of the aryl at C5 of the pyrrole ring affects the antimicrobial activity.

ACCESSION NUMBER: 1989:36649 HCAPLUS
DOCUMENT NUMBER: 110:36649
TITLE: Compounds with antibacterial and antifungal activity. Part IV. Synthesis and microbiological activity of new 1,5-diarylpyrrole derivatives
AUTHOR(S): Scalzo, M.; Porretta, G. C.; Chimenti, F.; Casanova, M. C.; Panico, S.; Simonetti, N.
CORPORATE SOURCE: Dip. Chim. Tecnol. Sostanze Biol. Attive, Univ. "La Sapienza", Rome, Italy
SOURCE: Farmaco, Edizione Scientifica (1988), 43(9), 665-76
CODEN: FRPSAX; ISSN: 0430-0920
DOCUMENT TYPE: Journal
LANGUAGE: Italian
OTHER SOURCE(S): CASREACT 110:36649
IT 118209-76-0P 118209-77-1P 118209-78-2P
118209-80-6P 118209-81-7P 118209-82-8P

118209-83-9P 118209-84-0P 118209-85-1P
118209-87-3P 118209-88-4P 118209-89-5P
118209-91-9P 118209-92-0P 118209-93-1P
118209-94-2P 118209-95-3P 118209-97-5P
118209-98-6P 118209-99-7P 118210-01-8P
118210-02-9P 118210-03-0P 118210-05-2P
118210-06-3P 118210-07-4P 118228-53-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antimicrobial activity of)

RN 118209-76-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclohexyl-2-methyl-1-(4-nitrophenyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 118209-77-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-dodecyl-2-methyl-1-(4-nitrophenyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 118209-78-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-hexyl-2-methyl-1-(4-nitrophenyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 118209-80-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-cyclohexyl-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 118209-81-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-dodecyl-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 118209-82-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-hexyl-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 118209-83-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclohexyl-1-(2,4-dichlorophenyl)-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 118209-84-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 118209-85-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-hexyl-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 118209-87-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclohexyl-2-methyl-5-(2-nitrophenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118209-88-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-dodecyl-2-methyl-5-(2-nitrophenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118209-89-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-hexyl-2-methyl-5-(2-nitrophenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118209-91-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-cyclohexyl-2-methyl-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118209-92-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-hexyl-2-methyl-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118209-93-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclohexyl-1-(2,4-dichlorophenyl)-2-methyl-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118209-94-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118209-95-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-hexyl-2-methyl-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118209-97-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclohexyl-2-methyl-5-(3-nitrophenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118209-98-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-dodecyl-2-methyl-5-(3-nitrophenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118209-99-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-hexyl-2-methyl-5-(3-nitrophenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118210-01-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-cyclohexyl-2-methyl-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118210-02-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-dodecyl-2-methyl-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118210-03-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-hexyl-2-methyl-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118210-05-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclohexyl-1-(2,4-dichlorophenyl)-2-methyl-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118210-06-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118210-07-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-hexyl-2-methyl-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118228-53-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-dodecyl-2-methyl-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 21 Jan 1989
GI



I

AB The synthesis and antifungal activities of the new 1,5-diarylpyrrole derivs. I (R = NO2, Cl; R1 = HNC6H13, HNC12H25, N-methylpiperazinyl, cyclohexylamino; R2 = F, Cl, Br, Me, OMe; n = 1 or 2) are reported. The N-methylpiperazinyl substituent is fundamental to activity. The presence of substituents at the para position of the two Ph rings and the presence of halogen atoms enhance microbiol. activity. The results are discussed in relation to structure-activity relationships.

ACCESSION NUMBER: 1989:20996 HCAPLUS
DOCUMENT NUMBER: 110:20996
TITLE: Compounds with antibacterial and antifungal activity. Part V. Synthesis and microbiological activity of new 1,5-diarylpyrrole derivatives
AUTHOR(S): Scalzo, M.; Porretta, G. C.; Chimenti, F.; Bolasco, A.; Casanova, M. C.; Simonetti, N.; Villa, A.
CORPORATE SOURCE: Dip. Chim. Tecnol. Sostanze Biol. Attive, Univ. "La Sapienza", Rome, Italy
SOURCE: Farmaco, Edizione Scientifica (1988), 43(9), 677-91
CODEN: FRPSAX; ISSN: 0430-0920
DOCUMENT TYPE: Journal
LANGUAGE: Italian
OTHER SOURCE(S): CASREACT 110:20996

IT 118179-23-0P 118179-24-1P 118179-25-2P
118179-27-4P 118179-28-5P 118179-29-6P
118179-31-0P 118179-32-1P 118179-33-2P
118179-35-4P 118179-36-5P 118179-37-6P
118179-39-8P 118179-40-1P 118179-41-2P
118179-43-4P 118179-44-5P 118179-45-6P
118179-47-8P 118179-48-9P 118179-49-0P
118179-51-4P 118179-52-5P 118179-54-7P
118179-55-8P 118179-56-9P 118179-58-1P
118179-59-2P 118179-60-5P 118179-62-7P
118179-63-8P 118179-64-9P 118179-66-1P
118179-67-2P 118179-68-3P 118179-70-7P
118179-71-8P 118179-72-9P 118179-74-1P
118179-75-2P 118179-76-3P 118209-17-9P
118209-18-0P 118209-19-1P 118210-84-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antimicrobial activity of)
RN 118179-23-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-cyclohexyl-5-(4-fluorophenyl)-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-24-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-N-hexyl-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-25-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-dodecyl-5-(4-fluorophenyl)-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-27-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-cyclohexyl-5-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-28-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-5-(4-fluorophenyl)-N-hexyl-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-29-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-dodecyl-5-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-31-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclohexyl-1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-32-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-N-hexyl-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-33-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-5-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-35-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-N-cyclohexyl-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-36-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-N-hexyl-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-37-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-N-dodecyl-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-39-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1,5-bis(4-chlorophenyl)-N-cyclohexyl-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-40-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1,5-bis(4-chlorophenyl)-N-hexyl-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-41-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1,5-bis(4-chlorophenyl)-N-dodecyl-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-43-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-N-cyclohexyl-1-(2,4-dichlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-44-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-hexyl-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-45-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-47-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-N-cyclohexyl-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-48-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-N-hexyl-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-49-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-N-dodecyl-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-51-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-1-(4-chlorophenyl)-N-cyclohexyl-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-52-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-1-(4-chlorophenyl)-N-hexyl-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-54-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-N-cyclohexyl-1-(2,4-dichlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-55-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N-hexyl-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-56-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-58-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclohexyl-2-methyl-5-(4-methylphenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-59-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-hexyl-2-methyl-5-(4-methylphenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-60-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-dodecyl-2-methyl-5-(4-methylphenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-62-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-cyclohexyl-2-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 118179-63-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-hexyl-2-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 118179-64-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-dodecyl-2-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 118179-66-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclohexyl-1-(2,4-dichlorophenyl)-2-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 118179-67-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-hexyl-2-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 118179-68-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 118179-70-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclohexyl-5-(4-methoxyphenyl)-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-71-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-hexyl-5-(4-methoxyphenyl)-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-72-9, HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-dodecyl-5-(4-methoxyphenyl)-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-74-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-cyclohexyl-5-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-75-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-hexyl-5-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-76-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-dodecyl-5-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 118209-17-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-cyclohexyl-1-(2,4-dichlorophenyl)-5-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 118209-18-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-hexyl-5-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 118209-19-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-5-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 118210-84-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-1-(4-chlorophenyl)-N-dodecyl-2-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
GI


I


II


III

AB The title compound (I) was prepared by reaction of o-H2NC6H4CONH2 with SOCl2. I reacted with 2-amino-1,4,5-triphenyl-3-pyrrolecarboxamide to give pyrrolothiadiazinone II. Chlorination of I with SCl2 or SO2Cl2 gave 2,5-H2NClC6H3CONH2. Bromination of I with Br at 0° gave 2,5-H2NBrC6H3CONH2 and at 20° gave 2,3,5-H2NBr2C6H2CONH2. I and Me2CO gave quinazoline III.

ACCESSION NUMBER: 1981:407231 HCAPLUS
DOCUMENT NUMBER: 95:7231
TITLE: Synthesis and reactions of 1,3-didehydro-2,1,3-benzothiadiazin-4-one
AUTHOR(S): Eger, Kurt
CORPORATE SOURCE: Pharm. Inst., Univ. Bonn, Bonn-Endenich, 5300, Fed. Rep. Ger.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1981), 314(2), 176-80
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 95:7231

IT 56023-01-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with didehydrobenzothiadiazinone, pyrrolothiadiazinone derivative from)

RN 56023-01-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-amino-1,4,5-triphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
GI


I


II


III

AB Thiadiazines I (X = PhCH2N, PhCH2CH2N, cyclohexylimino, Me(CH2)5N, MeN, Me2CHN, Me2N(CH2)3N, O) were prepared by treating the amides II (R = Ph) with SOCl2, SCl2, or S2Cl2. The thiadiazine oxides III [R = Me, R2 = (CH2)4] were prepared by reaction of II (X = S) with SOCl2. II were prepared by hydrolysis of the corresponding nitriles.

ACCESSION NUMBER: 1981:208819 HCAPLUS
DOCUMENT NUMBER: 94:208819
TITLE: Synthesis of bicyclic 1,2,6-thiadiazines
AUTHOR(S): Offermann, Wolfgang; Eger, Kurt; Roth, Hermann J.
CORPORATE SOURCE: Pharm. Inst., Univ. Bonn, Bonn-Endenich, 5300, Fed. Rep. Ger.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1981), 314(2), 168-75
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 94:208819

IT 56023-01-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with sulfur)
RN 56023-01-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-amino-1,4,5-triphenyl- (9CI) (CA INDEX NAME)



IT 77651-28-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cyclization with disulfur dichloride)
RN 77651-28-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-amino-1-cyclohexyl-4,5-diphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 26 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
GI



I



II

AB The title pyrrole derivs. (I; R, R1 = CH2CO2Et, OEt; CH2CO2H, OH; α-naphthyl, OEt; α-naphthyl, NHNH2; o-tolyl, OEt; α-naphthyl, OH; o-tolyl, OH; o-tolyl, NHNH2; o-tolyl, NHN:CHPh) were prepared by Knorr-Paal synthesis. Thus, 2 g II and 1 g α-naphthylamine in 1,4-dioxane were refluxed 3 h and the oily residue refluxed in 20% KOH-EtOH to give 66% I (R = α-naphthyl, R1 = OH).

ACCESSION NUMBER: 1981:174785 HCAPLUS
DOCUMENT NUMBER: 94:174785
TITLE: Synthesis of sterically hindered polysubstituted pyrroles
AUTHOR(S): Hua, Wen-Ting
CORPORATE SOURCE: Dep. Chem., Peking Univ., Peking, Peop. Rep. China
SOURCE: Huaxue Tongbao (1980), (11), 662-4
CODEN: HHTPAU; ISSN: 0441-3776
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

IT 77412-53-4P 77412-54-5P 77418-98-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 77412-53-4 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 2-methyl-1-(2-methylphenyl)-5-(2-naphthalenyl)-, (phenylmethylene)hydrazide (9CI) (CA INDEX NAME)



RN 77412-54-5 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 2-methyl-1-(2-methylphenyl)-5-(2-naphthalenyl)-, hydrazide (9CI) (CA INDEX NAME)



RN 77418-98-5 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 2-methyl-1-(1-naphthalenyl)-5-(2-naphthalenyl)-, hydrazide (9CI) (CA INDEX NAME)



L4 ANSWER 27 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
GI


I


II


III

AB The pyrrolothiadiazine I was formed by treating the pyrrolecarboxamide II (R = CONH2, R1 = NH2) with SOCl2 in dioxane at 90°, in THF at 20°, or in DMF at 0°. The same reaction in DMF 30° gave I (R = CN, R1 = N:CHNMe2) and at 80-100° gave III (X = CHNMe2) in acetone at 20-30° III (X = CMe2) was obtained.

ACCESSION NUMBER: 1977:55398 HCAPLUS
DOCUMENT NUMBER: 86:55398
TITLE: Formation of a novel ring system: pyrrolo[2,3-e]-thiadiazine
AUTHOR(S): Kim-Su, Myungeun; Eger, Kurt; Roth, Hermann J.
CORPORATE SOURCE: Pharm. Inst., Univ. Bonn, Bonn, Fed. Rep. Ger.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1976), 309(9), 721-4
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: German

IT 56023-01-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with thionyl chloride, solvent effect on)

RN 56023-01-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-amino-1,4,5-triphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 28 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB The title ring systems (I, X = N, S) were obtained by hydrolyzing the pyrrole II (R = CN) with polyphosphoric acid-H3PO4 and cyclizing II (R = CONH2) with NaNO2 or SOCl2. Hydrolysis of II (R = CN) with 100% H3PO4 gave II (R = CO2H).

ACCESSION NUMBER: 1975:428198 HCAPLUS
DOCUMENT NUMBER: 83:28198
TITLE: Two new rings systems. Pyrrolo[2,3-d]azimide and pyrrolo[2,3-e]thiadiazine
AUTHOR(S): Roth, H. J.; Eger, K.
CORPORATE SOURCE: Pharm. Inst., Univ. Bonn, Bonn, Fed. Rep. Ger.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1975), 308(3), 186-9

CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: German

IT 56023-01-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of, with nitrite or thionyl chloride)
RN 56023-01-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-amino-1,4,5-triphenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 29 OF 29 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 16 Dec 2001
GI For diagram(s), see printed CA Issue.
AB 1,2,5-Triphenyl-3-pyrrolecarboxylic acid and SOCl2 give the chloride (I) as a red resin; the anilide, from I and PhNH2 in boiling C6H6, m. 171°; Me ester, m. 156-7°. I and C6H6 with AlCl3 give 1,2,4-triphenyl-3-benzoylpyrrole, yellow, m. 238°. PhCH2COCH2CO2Et and PhCOCH2Br with Na give Et γ-phenyl-α-phenacylacetoacetate (II) which with NH3 in EtOH yields Et γ-phenyl-α-phenacyl-β-aminocrotonate, m. 166-7°; N H2SO4 gives 5-phenyl-2-benzyl-3-pyrrolecarboxylic acid, m. 181°; Et ester, m. 137°; the acid chloride could not be prepared II and PhNH2 in AcOH give 1,5-diphenyl-2-benzyl-3-pyrrolecarboxylic acid, m. 191°; Et ester, m. 100-1°; again the acid chloride could not be prepared PhCH2COCO2Et and PhNMeNH2 in 2 N HCl give 1-methyl-3-phenyl-2-indolecarboxylic acid (IIA), m. 197-8°; chloride (III), b0.5 180°, m. 100°. III and C6H6 with Al l3 give 1-methyl-1'-oxoindeno[2',3',2,3]indole (IV), reddish brown, m. 147-8°; 2,4-dinitrophenylhydrazone, brownish violet, m. 313-14°. With concentrated H2SO4 IIA gives 1-methyl-3-phenylindole, m. 65°. Et benzoylacetate asymmethylphenylhydrazone, yellow, 128°; HCl in EtOH gives the Et ester, m. 97° (picrate, yellow, m. 137-8°), of 1-methyl-2-phenyl-3-indolecarboxylic acid, m. 201-2°; the chloride and C6H6 with AlCl3 give 1-methyl-2-phenyl-3-benzoylindole, yellow, m. 130°; 2,4-dinitrophenylhydrazone, deep red, m. 269°. 1-Methyl-3-benzyl-2-indolecarboxylic acid, m. 194°; the chloride, yellow, m. 117-18°; AlCl3 and C6H6 give 9-methyl-2,3-benzo-1-oxo-1,4-dihydrocarbazole (V), yellow, m. 215-16°. 3-Phenyl-2-indolecarboxylic acid, m. 186°; chloride, pale yellow, m. 164° (decomposition), which then does not m. at 360°; the chloride on heating at 175-80° or with AlCl3 in PhNO2 gives 3',3''-diphenyl-1,2,4,5,1',2',1'',2''-diindolo-3,6-diketopiperazine (VI), yellow powder. VI heated with C5H5N or N2H4.H2O at 200° gives 3-phenyl-2-indolecarboxylic hydrazide, m. 227°; benzylidene compound, m. 237°. Phenylpyruvic acid 4-toluylhydrazone, yellow, m. 145-6°; alc. HCl gives 5-methyl-3-phenyl-2-indolecarboxylic acid,